Copeptin: Physiology and What Research Reports

What Copeptin Is

Copeptin is the C-terminal fragment of pre-pro-vasopressin, the precursor protein that also gives rise to arginine vasopressin (AVP, also called antidiuretic hormone) and neurophysin II. When the precursor is processed and secreted, copeptin is released into the circulation in a one-to-one molar ratio with AVP. It has no established hormonal action of its own in humans; its research value comes almost entirely from the fact that it tracks vasopressin release while being much easier to measure.

AVP itself is notoriously difficult to quantify: it is small, largely bound to platelets, cleared quickly, and unstable in stored plasma. Copeptin, by contrast, is larger, remains stable at room temperature for extended periods, and can be measured with standard immunoassays. A 2022 review of copeptin in fluid disorders and stress described this stability as the reason copeptin became the practical surrogate for vasopressin secretion in both clinical and research settings (PMID 35143773).

Why readers of peptide literature encounter the term

Copeptin is not a therapeutic peptide and is not administered to anyone. It appears in peptide-adjacent reading for three reasons: it is a peptide fragment produced by the posterior pituitary axis; it is the read-out used in stimulation tests that also involve peptide and amino-acid stimuli such as arginine; and it is frequently reported as a non-specific biomarker of physiological stress in studies of other hormones, including growth hormone.

Where Copeptin Comes From and What It Reflects

Pre-pro-vasopressin is synthesised in magnocellular neurons of the hypothalamic supraoptic and paraventricular nuclei, transported down axons to the posterior pituitary, and released into the bloodstream. The classical triggers for release are rising plasma osmolality detected by hypothalamic osmoreceptors, and falling blood volume or blood pressure detected by baroreceptors. Non-osmotic triggers include nausea, pain, hypoglycaemia and acute physiological stress — which is why copeptin rises in many acute illnesses that have nothing to do with water balance, as the 2022 review on fluid disorders and stress summarised (PMID 35143773).

Downstream, AVP acts on V2 receptors in the renal collecting duct to promote water reabsorption, and on V1a receptors in vascular smooth muscle. Copeptin does not participate in these actions; it is simply co-secreted. In practice, a copeptin measurement is interpreted as an indirect estimate of how much vasopressin the pituitary released around the time of sampling.

How Copeptin Is Measured and Studied

Copeptin is measured in plasma or serum by sandwich immunoassay. Two broad approaches appear in the literature:

• Baseline (unstimulated) copeptin — a single sample, used in observational and biomarker studies.
• Stimulated copeptin — samples drawn before and after a provocative stimulus designed to raise vasopressin output, used diagnostically.

Stimulation testing in adults

A 2023 study in the New England Journal of Medicine compared arginine-stimulated copeptin with hypertonic saline-stimulated copeptin for distinguishing AVP deficiency (central diabetes insipidus) from primary polydipsia, and researchers reported that hypertonic saline-stimulated copeptin achieved higher overall diagnostic accuracy than the arginine-stimulated test (PMID 37966286). That comparison matters because the two tests differ in burden: hypertonic saline testing requires repeated sodium monitoring, whereas arginine infusion is simpler to run.

Stimulation testing in children

A 2023 study in Clinical Endocrinology evaluated arginine-stimulated copeptin in children and adolescents, and the study reported copeptin responses in this younger population to assess whether the adult approach could be extended to paediatric testing (PMID 36710502). A separate 2024 paper evaluated copeptin measured during clonidine or L-Dopa stimulation — stimuli normally used for growth hormone testing — and researchers examined whether copeptin responded usefully to those agents in children (PMID 38462927). A 2023 case series described copeptin levels in hospitalised infants and children with suspected vasopressin-dependent disorders, reporting how values behaved in a real inpatient population rather than a controlled test setting (PMID 37029788).

What the Literature Reports

Sodium and water balance

Copeptin has been studied as a tool for sorting out the cause of low serum sodium. A 2025 study in the Journal of Clinical Endocrinology & Metabolism reassessed the role of copeptin in emergency department admissions for hypotonic hyponatraemia, and the authors reported on how well copeptin separated the underlying aetiologies in that acute setting (PMID 40317183). The recurring theme across this literature is that copeptin is informative but rarely stands alone, because so many non-osmotic stimuli also raise it (PMID 35143773).

Kidney function

A 2023 population study in Endocrine Journal examined copeptin in the general Japanese population and reported an association between copeptin and microalbuminuria as well as measures of renal function (PMID 37286517).

Acute cardiovascular and neurological conditions

Because copeptin rises with acute stress, it has been tested as a prognostic marker outside endocrinology. A 2018 prospective study in Scientific Reports assessed copeptin for diagnosis and prognosis in patients presenting with suspected acute aortic syndromes (PMID 30425269). A 2023 paper examined copeptin implementation in stroke prognosis (PMID 36648972), and a 2017 study evaluated copeptin as a potential biomarker in tick-borne encephalitis (PMID 27882774).

Endocrine and psychiatric contexts

A 2022 paper in the Journal of Clinical Medicine measured copeptin in growth hormone-treated patients (PMID 36233377), and a 2020 study in Brain and Behavior reported copeptin measurements in anorexia nervosa, a condition in which fluid balance and stress physiology are both disturbed (PMID 32073757).

Copeptin Testing: What Studies Report

Copeptin is a measured analyte, not an administered substance, so the tolerability questions in the literature concern the stimuli used to provoke its release rather than copeptin itself. The 2023 comparative trial of arginine and hypertonic saline stimulation assessed both diagnostic performance and the practical demands of each protocol, and researchers reported that the higher-accuracy hypertonic saline approach involves the more intensive testing procedure (PMID 37966286). Studies in children likewise evaluated whether alternative stimuli already used in paediatric endocrine testing could serve the same purpose (PMID 38462927).

Interpreting the Evidence

Three limitations recur. First, copeptin is non-specific: acute stress of almost any kind can raise it, which complicates its use as a stand-alone marker (PMID 35143773). Second, assay platforms and cut-off values differ between studies, so thresholds are not always transferable. Third, much of the prognostic literature is observational. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, laboratory test or treatment decision.

References

• Arginine or Hypertonic Saline-Stimulated Copeptin to Diagnose AVP Deficiency (The New England Journal of Medicine, 2023)
• Copeptin in fluid disorders and stress (Clinica Chimica Acta, 2022)
• Reassessing the Role of Copeptin in Emergency Department Admissions for Hypotonic Hyponatremia (The Journal of Clinical Endocrinology and Metabolism, 2025)
• Arginine-stimulated copeptin in children and adolescents (Clinical Endocrinology, 2023)
• Evaluation of copeptin in children after stimulation with clonidine or L-Dopa (Journal of Pediatric Endocrinology & Metabolism, 2024)
• Copeptin levels in hospitalized infants and children with suspected vasopressin-dependent disorders: a case series (Journal of Pediatric Endocrinology & Metabolism, 2023)
• Copeptin is associated with microalbuminuria and renal function in the general Japanese population (Endocrine Journal, 2023)
• Prospective diagnostic and prognostic study of copeptin in suspected acute aortic syndromes (Scientific Reports, 2018)
• Copeptin Implementation on Stroke Prognosis (Neurology International, 2023)
• Usefulness of copeptin as a potential biomarker in TBE (Biomarkers, 2017)
• Copeptin in Growth Hormone-Treated Patients (Journal of Clinical Medicine, 2022)
• Copeptin in anorexia nervosa (Brain and Behavior, 2020)